7 March 2008: EXACT`s cancer test recommended for screening in US

New Colon Cancer Screening Guidelines were issued in US on Wednesday, March 5. The guidelines includes for the first a time the stool DNA test developed by NorDiag`s partner EXACT Sciences Corp. (Nasdaq: EXAS) as a recommended test for screening of colorectal cancer.

The new guidelines were released by the Cancer Society, the American College of Radiology, and the U.S. Multi-Society Task Force on Colorectal Cancer, which represents multiple gastroenterologist organizations in US.

NorDiag and EXACT released their partnership agreement in June 2007. EXACT granted a non-exclusive license to its proprietary DIA® (long-DNA) technology and related know-how to NorDiag for commercializing their colorectal cancer test in Europe, Japan and Australia.

DIA (long-DNA) is a proprietary biomarker discovered by researchers at EXACT Sciences that is used to identify, at the molecular level, the presence of abnormal cell death, which is typically a hallmark of cancer. When the marker is detected in stool samples of patients, multiple studies have shown both high sensitivity and specificity for the presence of colorectal cancer.

DIA (long-DNA) is one of the candidate markers to be included in NorDiag`s next generation test contributing to early diagnostics of colorectal cancer. NorDiag plans preclinical testing in Q3 this year to be followed by commercial launch next year.

- We have waited for this breakthrough for DNA based diagnostics for colorectal cancer, comments CEO in NorDiag, Mårten Wigstøl. - The decision of the medical experts in US paves the way for regular use of this method, and we expect a similar development in European countries, he says. Even more important - NorDiag is well positioned to capitalize on this development.

Contact:
CEO Mårten Wigstøl,
morten.wigstol@nordiag.com
+47 91165775

About NorDiag ASA:
NorDiag is a biotechnology company developing, manufacturing and marketing of automated solutions, instruments and tests, for diagnostic of cancer and infectious diseases. The Company`s first product in cancer diagnosis is Genefec TM for diagnosis of colorectal cancer. NorDiag has also launched a product for diagnostic of sexual transmitted infectious. In addition, the company has other applications for early diagnosis of cancer under development, as well as applications for other infectious diseases in the product pipeline. NorDiag is listed on Oslo Stock Exchange with the ticker NORD.